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Abstract. ethylmalonic encephalopathy (ee) is an autosomally 
recessive inherited disorder with a relentlessly progressive 
decline in neurological function, usually fatal by the age of 
ten. it is characterised by generalised hypotonia, psychomotor 
regression, spastic tetraparesis, dystonia, seizures and, eventually, 
global neurological failure. approximately 50 reports have 
been published worldwide describing this devastating disease, 
most involving patients of Mediterranean or arab origin. The 
fundamental defect in ee likely involves the impairment of a 
mitochondrial sulphur dioxygenase coded by the eTHe1 gene 
responsible for the catabolism of sulphide, which subsequently 
accumulates to toxic levels. a diagnosis of ee should initiate 
careful genetic evaluation and counselling, particularly if the 
parents intend to have additional offspring. The present report 
describes the diagnosis of ee in a reproductive endocrinology 
context, where both members of a non-consanguineous couple 
were confirmed to be carriers of an identical A→G mutation. 
This previously unknown mutation at nucleotide position c.494 
resulted in an amino acid substitution, p.asp165Gly. although 
consideration was given to in vitro fertilisation, embryo biopsy 
and single gene pre-implantation genetic diagnosis, the couple 
decided to first utilise a less aggressive therapeutic approach 
with donor sperm insemination. Pregnancy with a low risk 
of ee was indeed achieved; however, the infant was affected 
with a different anomaly (hypoplastic left heart). as this case 
demonstrates, prior to the initiation of fertility therapy, genetic 
analysis may be used to provide a confirmatory diagnosis when 
ee is suspected.
Case report
Clinical presentation. The patient, aged 36½ years, sought 
reproductive endocrinology consultation with her husband. She 
suffered from mild hypothyroidism and pernicious anaemia, 
which were medically managed and stable before presentation. 
Her blood type was o+. neither partner smoked and both were 
in good general health. The ethnicity of both partners was 
caucasian, and there was no family history of any genetic 
condition. consanguinity was absent. The couple had achieved 
a total of four pregnancies together, none of which had required 
medical assistance. The first two pregnancies yielded term male 
deliveries, both via caesarean. The second two pregnancies 
ended in miscarriage, one each in the first and second trimester. 
The second delivery resulted in the birth of a son who 
evidenced developmental delay at the age of approximately 
six months. Paediatric neurology assessment of this infant 
included EEG and brain MR, which revealed non-specific 
abnormalities. initial investigations for spastic diplegia and 
global developmental delay included the measurement of blood 
lactate, which was elevated, and of urine organic acids, which 
revealed high ethylmalonic acid and methylsuccinate. a defect 
in fatty acid oxidation was thus suspected, with short chain 
acyl-coA dehydrogenase deficiency (SCAD) and ethylmalonic 
aciduria considered as provisional diagnoses. a study of 
fatty acid β-oxidation in fibroblasts excluded medium- and 
long-chain fatty acid defects. The serum acylcarnitine profile 
revealed elevated butyrylcarnitine, which did not exclude 
Scad. Muscle biopsy showed diminished cytochrome oxidase; 
spectrophotometric dosage of respiratory chain complexes on 
the sample confirmed deficiency of mitochondrial complex IV. 
Gene sequencing for Scad and ethylmalonic encephalopathy 
identified no mutations in the ACADS gene (SCAD), but 
did identify a novel mutation in eTHe1. This mutation was 
determined to be homozygous by confirmation of carrier 
status via blood samples from both parents of the proband. a 
treatment regimen was started for the proband, and the parents 
were advised that any future pregnancies would have a 25% 
risk of being affected with ee. The parents understood that 
the metabolic derangements associated with the mitochondrial 
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abnormalities were secondary to ee, and did not constitute a 
separate diagnosis. 
The couple were seen by a genetic counsellor over a two-
year period. They were aware that early implementation of 
any therapy for a baby affected with ee would not change 
the course of disease in that child. Treatment options included 
gonadotropin ovulation induction and insemination (iui) using 
anonymous donor sperm or, if native gametes were preferred, 
IVF incorporating pre-implantation genetic diagnosis (PGD), 
which permits the selection of unaffected embryos prior to 
transfer. as ee is a very rare condition with a hypothetical 
maximum 1:250 carrier rate under hardy-Weinberg equilib-
rium, iui using anonymous donor sperm would result in a risk 
of <1:1000 of offspring having ee.
At our centre, a gynaecological exam identified no abnor-
malities, and transvaginal saline infusion ultrasound (with 
enhancement) confirmed an unremarkable intrauterine contour 
and fallopian tubal patency. Pap test and cervical cultures 
were negative. The patient was confirmed to have mild 
PcoS, and the administration of 500 mg glucophage thrice 
daily, which had been started about one year previously, was 
maintained. Thrombophilia panel and other laboratory tests 
were normal, although a substantially elevated anti-thyroid 
antibody titre of 115.2 iu/ml (reference range 0-4.11 iu/ml) 
was noted. additionally, anti-thyroid peroxidise antibody was 
>1,000 kiu/l (reference range 0-5.6 kiu/l) and serum iga titre 
was marginally high at 2.96 g/l (reference range 0.84-2.69). 
Pulsed doppler ultrasound of the thyroid was negative for 
nodularity or abnormal flow patterns. The husband's semen 
analysis was normal. 
Sequencing protocol. dna was supplied as blood spots on 
Guthrie cards or purified from whole blood. Generations reagents 
(Gentra Systems, Minneapolis, Mn, uSa) were used to isolate 
dna. references to nucleotides or amino acids were based 
on the cdna sequence of eTHe1 (nM 014297), so that the 
initiating aTG codon was numbered as bp 1-3 and the initiator 
methionine was designated amino acid 1. Primers for Pcr 
amplification of the seven EThE1 exons were configured as 
previously described (1). The following primers were tagged 
with a terminal M13 nucleotide sequence to facilitate subsequent 
cycle sequence reactions: exon1 F: 5'-TGTaaaacGacGGcc 
aGTTccGTGGccccTTTaGGcGT-3'; exon1 r: 5'-caG 
GaaacaGcTaTGacccccGGaGTTccGTccTTGcT-3'; 
exon2 F: 5'-TGTaaaacGacGGccaGTaGcaaGGacGG 
aacTccGGG-3'; exon2 r: 5'-caGGaaacaGcTaTGacc 
TcccaTTccacTGacGcTGca-3'; exon3 F: 5'-TGTaaa 
acGacGGccaGTTGcaGcGTcaGTGGaaTGGa-3'; 
exon3 r: 5'-caGGaaacaGcTaTGaccaaGaaGTccaG 
Gccaccacc-3'; exon4 F: 5'-TGTaaaacGacGGccaGTG 
GGccaGTTTcaTcTaGaaGGc-3'; exon4 r: 5'-caGGaa 
acaGcTaTGaccGcccccTaaaaGTcTaaTGTcc-3'; 
exon5 F: 5'-TGTaaaacGacGGccaGTGGaaGGGGTTaG 
aGTcTTcTGT-3'; exon5 r: 5'-caGGaaacaGcTaTGacc 
GaGacTGGTcGTcTTcaTGcc-3'; exon6 F: 5'-TGTaaa 
acGacGGccaGTaGTTcTGaGaGGccTGaGGca-3'; 
exon6 r: 5'-caGGaaacaGcTaTGaccacccaGGaGTcc 
aaGacccca-3'; exon7 F: 5'-TGTaaaacGacGGccaGT 
aGTGGGGccTGGaacTcTac-3'; exon7 r: 5'-caGGaa 
acaGcTaTGacccGGcccaGaaacccaaTTGG-3'.
PCR amplification was conducted at 96˚C for 15 min (initial 
cycle) followed by 40 cycles at 95˚C for 1 min, 59˚C for 30 sec 
and 72˚C for 2 min. A final cycle was carried out at 72˚C for 
5 min. Sequence reactions were prepared using the bigdye 
Terminator kit 1.1 (applied biosystems, Foster city, ca, uSa). 
nucleotide sequence data were collected on an abi PriSM® 
3100-avant Genetic analyzer and analysed via Sequencher v3.1 
(Gene codes corp., ann arbor, Mi, uSa). Sequence primers 
were forward and reverse M13 oligonucleotides, except for the 
reverse primer to the exon6 sequence. due to repeat sequences 
at intron6, a specific sequence primer was used: 5'-AGTCCA 
GGTccccaGcTG-3'.
Results and clinical outcome. Genotype analysis revealed 
that both parents had an identical a→G mutation at nucleotide 
position c.494, resulting in an amino acid substitution, 
p.Asp165Gly (Fig. 1). This specific mutation has not been 
previously identified (2), but is considered to be disease-
associated as it was absent in 56 control individuals, and no 
other amino acid-modifying sequence alteration was detected in 
the analysed sequences. Follow-up consultation with a genetic 
counsellor was provided. Since the couple desired another 
Figure 1. diagram of the eTHe1 gene (19q13.32) with previously reported representative mutations and associated exon for each. a new a→G mutation at 
c.494 (circled above exon4) was associated with a p.asp165Gly substitution.
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pregnancy, they were offered either ovulation induction with 
intrauterine insemination (iui) using anonymous donor sperm 
or (if native gametes were preferred) IVF with pre-implantation 
genetic diagnosis before transfer to select unaffected embryos. 
They decided to pursue iui, and a 75 iu/day r-FSH regime 
was initiated without pituitary down-regulation. Given the 
anti-thyroid antibody titre and history of two miscarriages 
before presentation, 5,000 µ/day s.c. heparin, 20 mg/day oral 
prednisolone and 75 mg/day aspirin was started empirically at 
the time of follicular recruitment (3,4). The ovulation induction 
response was monitored by periodic follicular assessment via 
transvaginal ultrasound and serum estradiol determinations. 
donor insemination was performed 36 h after 10,000 iu s.c. 
hCG administration to trigger ovulation. Though the first 
iui cycle failed to achieve pregnancy, the patient returned 
the following month and a second attempt using the same 
protocol was undertaken. For both treatment cycles, the same 
anonymous donor was used, with samples obtained from 
a danish sperm bank. Fourteen days after her second iui, a 
positive pregnancy test was obtained. Transvaginal ultrasound 
confirmed a single intrauterine pregnancy at a gestational 
age of seven weeks, with positive embryonic cardiac action 
(rate 107/min). antepartum surveillance by targeted (level ii) 
ultrasound was consistent with hypoplastic left heart syndrome, 
a diagnosis confirmed during additional testing performed 
during the second trimester. amniocentesis revealed a euploid 
pregnancy with an inversion of 5q12q13. FiSH analysis 
showed normal coverage (whole chromosome staining) for 
both chromosome 5 homologues and no 22q11.2 deletion. 
The couple declined karyotyping to determine whether this 
was an inherited or de novo disorder. Sadly, an intrauterine 
fetal demise occurred at approximately 32 weeks, and placenta 
accreta necessitated a caesarean hysterectomy.
Discussion
This is the first published description of ethylmalonic enceph-
alopathy (ee) encountered in a clinical infertility setting, and 
the only known case from ireland. ee is a very rare autosomal 
recessive inborn error of metabolism caused by mutations in 
the eTHe1 gene localised to chromosome 19q13. a mutation 
at this site has been shown to result in functional impairment 
of a mitochondrial sulphur dioxygenase, responsible for 
sulphide catabolism (5). While the exact incidence of EE is 
unknown, only some 50 cases have been reported worldwide 
(2). Thus far, most affected individuals have been of arab or 
Mediterranean origin.
EE usually manifests as neurological delay within the first 
year of life, and is progressively catastrophic. it is typically 
accompanied by chronic diarrhoea, widespread lesions of 
small vessels resulting in showers of petechiae (particularly 
during intercurrent infection), easy bruising and orthostatic 
acrocyanosis (6). biochemical features of ee include reduced 
mitochondrial respiratory complex IV activity in skeletal 
muscle, persistent lactic acidaemia and markedly elevated 
urinary excretion of ethylmalonic acid (eMa) and methyl-
succinic acid (7). Patients with milder expression of ee have 
been treated with supplementary l-carnitine, riboflavin, Q10, 
as well as other vitamin therapies, which may improve energy 
metabolism and reduce oxidative stress. The clinical hetero-
geneity of ee was recently illustrated by monochorionic 
twins with the condition, where one had an episode of coma 
at age 3 and now has spastic quadraparesis and cannot speak. 
The other twin freely uses her upper extremities; pyramidal 
symptoms are limited to lower extremities, and she speaks 
two languages (8). 
Any provisional diagnosis of EE should be verified by 
testing of the urine for the pathologic accumulation of eMa, 
methylsuccinic acid and/or c4-c6 acylglycines (isobutyryl-, 
isovaleryl-, 2-methylbutyryl- and hexanoylglycine). Serum 
levels of c4-c6 carnitines (butyryl-, isobutyryl-, isovaleryl- and 
hexanoylcarnitine) may also be elevated. urine and blood test 
results obtained in ee may be similar to those noted in multiple 
acyl-CoA dehydrogenase deficiency (MADD) or short chain 
acyl-CoA dehydrogenase deficiency (SCADD), where elevated 
urinary eMa can exist with or without serum butyrylcarnitine 
elevation. accordingly, Madd and Scadd are often included 
in the differential diagnosis of EE until definitive (genotype) 
testing can be performed (9,10). at least in severe ee, the 
recurrent petechiae, orthostatic acrocyanosis and chronic 
diarrhoea seem to be specific for this condition. The massive 
urinary excretion of thiosulfate classically observed in ee has 
been experimentally replicated in a knockout ethe1(-/-) murine 
model; the resultant sulfide tissue accumulation potently inhibits 
coX and short-chain fatty acid oxidation. The vasoactive and 
vasotoxic effects of this sulfide excess appear to explain the 
microangiopathy present in ee patients (5).
Genetic counselling should be offered when the diagnosis 
of EE is confirmed. In the present case, genetic sequencing 
identified the same novel mutation in both husband and 
wife, a highly unusual statistical event for rare mutations in 
non-consanguineous pairing. The couple was aware that the 
chance of any subsequent pregnancy being affected with ee 
was 25%, and therefore sought reproductive endocrinology 
consultation to minimise this risk. While IVF with embryo 
biopsy and single gene pre-implantation genetic diagnosis was 
discussed, the couple decided to first utilise a less aggressive 
therapeutic approach of iui using donor sperm. although 
this treatment strategy did not incorporate native gametes 
from both partners, pre-iui psychological counselling was 
provided, and the patients were determined to be satisfactory 
candidates for donor iui. Parallel to this treatment, siblings 
of the carrier couple were offered similar testing to determine 
the carrier status of family members. While the patient did 
conceive from insemination with donor sperm, the baby was 
not healthy for reasons other than ee. it should be noted that, 
even if the couple had elected to undergo IVF with PGD, the 
anomaly encountered in the subsequent pregnancy would have 
escaped detection before embryo transfer.
in summary, this report presents a diagnostic evaluation 
and clinical management plan for fertility patients having 
a prior offspring with ee, and expands our knowledge of 
causative mutations for this disorder. While IVF incorporating 
pre-implantation genetic diagnosis could have been applied in 
this circumstance, our patient preferred to reserve deployment 
of IVF in favour of a more conservative approach. Additional 
clinical and laboratory research is needed to more fully 
characterise this rare condition, and definitive diagnosis 
remains a key objective before beginning any fertility 
treatment.
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